DTwP-Hb-Hib pentavalent vaccine - Indian Immunologicals

Drug Profile

DTwP-Hb-Hib pentavalent vaccine - Indian Immunologicals

Alternative Names: HBI Pentavalent vaccine

Latest Information Update: 23 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Indian Immunologicals
  • Class Haemophilus vaccines; Hepatitis B vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 06 Feb 2017 Indian Immunologicals completes a phase III trial in Tetanus, Pertussis, Hepatitis B, Haemophilus infections, Diphtheria (Prevention) in India (IM) (CTRI/2016/01/006541)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top